lnth-2403
·Code: LNTH-2403
lnth-2403: developed by 1 company · 1 clinical trial tracked.
lnth-2403 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect lnth-2403 to LNTH; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could lnth-2403 → LNTH affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 1 study sponsors
Related indications
head and neck, breast, lung, and pancreatic cancersColorectal CancerHead and Neck Squamous Cell CarcinomaNon-Small Cell Lung Cancer
Study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| Lantheus Holdings, Inc. (LNTH) head and neck, breast, lung, and pancreatic cancers | Preclinical |
Clinical Trials (1)
A Phase 1, Multicenter Study of the Safety and Imaging of NTH-2403, a Lutetium-177 Radiolabeled Monoclonal Antibody Targeting the LRRC15 Epitope, in Participants With Locally Advanced or Metastatic Solid Tumors
Primary endpoint: To assess the safety and tolerability of a single dose of LNTH-2403
Interventionalopen16 targetStarted 2026-10Completion 2027-101 site · AustraliaRadiopharm Theranostics, Ltd
Frequently asked questions
Who is developing lnth-2403?
lnth-2403 is being developed by Lantheus Holdings, Inc..
How many clinical trials involve lnth-2403?
BioSniper tracks 1 clinical trial involving lnth-2403.